ÂÜÀòÂÒÂ×

Dr. Latterich is a biotechnology executive with a strong mix of corporate leadership and academic experience.

Previously, he served as SVP of Technical Operation and Officer for Histogen (NASDAQ: HSTO), a publicly traded, clinical-stage biotechnology firm focusing on regenerative medicine, inflammatory disorders, and infectious disease. His past professional affiliations include the Salk Institute as Assistant Professor, Diversa (NASDAQ: VRNM) as Principal Scientist, Illumina (NASDAQ: ILMN) as

Director of Proteomics, McGill Medical School and the University of Montreal as Associate Professor, the Proteogenomics Research Institute for Systems Medicine as Professor, the Nicholas Conor Institute as CSO and co-founder, and ProterixBio, Inc. (formerly known as BioScale, Inc.) as CSO. Dr. Latterich's expertise is in the establishment and growth of science-focused research initiatives and commercial organizations, technology evaluation/acquisition, partnerships, and corporate leadership.

Author of 40 publications mostly in premier, peer-reviewed journals and one book; Editor-in-Chief of Proteome Science from 2002 to 2019. Dr. Latterich received grant funding from NIH, HFSP, March of Dimes, Pew Foundation, Genome Canada, Genome Quebec, CIHR and CFI. Dr. Latterich is a 1998 Pew Scholar and has held a prestigious Tier 1 Canada Research Chair at McGill University. He

performed post-doctoral training in the laboratory of the Nobel Laureate Randy Schekman at UC Berkeley. He received a B.Sc. in Molecular Biology and Biochemistry, as well as a Ph.D. from Durham University in the UK.